Table 2 Demographics and clinical presentations of COVID-19 patients and control group

Gender; Male/ Female (N, %)

48 (53.3%)/ 42 (46.7%)

28 (56%)/ 22 (44%)

Smoker/ Non-smoker

41 (45.5%)/ 49 (54.5%)

21 (42%)/ 29 (58%)

Age (Year, mean ± SD)

49.2 ± 13.4

48.3 ± 12.6

Duration of COVID-19 (Day)

10.9 ± 1.4

–

Oxygen saturation

91.8 ± 7.1

–

Systolic BP (mmHg)

138.7 ± 20.4

–

Diastolic BP (mmHg)

75.8 ± 9.9

–

WBC (cells/mm³)

9451 ± 1877.3

–

Neutrophil–lymphocyte ratio

10.4 ± 6.9

–

ALP (IU/L)

244.8 ± 42.9

–

AST (IU/L)

35.7 ± 11.3

–

ALT (IU/L)

36.4 ± 7.5

–

LDH (IU/L)

408.2 ± 97.1

–

CRP (mg/L)

5.1 ± 1.2

–

ESR (mm/h)

22.7 ± 10.3

–

BMI (kg/m²)

27.9 ± 7.1

–

Total cholesterol (mg/dl)

223.2 ± 41.9

–

TG (mg/dl)

173.7 ± 51.5

–

LDL (mg/dl)

144.2 ± 35.6

–

HDL (mg/dl)

49.2 ± 14.1

–

Creatinine (mg/dl)

1.87 ± 0.49

–

BUN (mg/dl)

24.4 ± 13.2

–

FBS (mg/dl)

101.5 ± 32.7

–

D-dimer (ng/ml)

1.74 ± 0.21

–

Cardiovascular diseases

12 (13.3%)

–

Diabetes

11 (12.2%)

–

Hypertension

16 (17.8%)

–

Fever

60 (66.6%)

–

Cough

59 (65.5%)

–

Dyspnea

55 (61.1%)

–

Sputum

39 (43.3%)

–

Vomiting/diarrhea

33 (36.7%)

–

Methylprednisolone use

29 (32.2%)

–

Remdesivir use

21 (23.3%)

–

Azithromycin use

12 (13.3%)

–

Anticoagulation therapy

16 (17.8%)

–